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INTRODUCTION:  Individuals  with  autosomal  dominant  polycystic  kidney  disease  (ADPKD)  frequently  suf-
fer  arterial  hypertension  even  prior  to signiﬁcant  loss  of  renal  function,  a  clinical  situation  that  obscures
detection  of  modiﬁable  secondary  causes  of hypertension.
PRESENTATION  OF  CASE:  A  50-year-old  man  with  ADPKD  and  polycystic  liver  and  resistant  hypertension
is  diagnosed  with  a 4-cm  right  adrenal  mass.  Cross-sectional  MRI is indicative  of  pheochromocytoma
versus  adrenocortical  carcinoma  or metastasis,  though  there  are  no  typical  PCC  symptoms  and  plasma  and
urine metanephrines  are  within  normal  ranges.  Since  malignancy  cannot  be  excluded,  right  adrenalec-
tomy  is  performed.  Considering  that the enlarged  liver  poses  an  obstacle  for transperitoneal  open  and
laparoscopic  approaches,  a retroperitoneoscopic  approach  is  used.  Surgical  pathology  reveals  a  4.5-cm
pheochromocytoma;  the  patient  no  longer  requires  antihypertensive  therapy.
DISCUSSION  & CONCLUSION:  Pheochromocytoma  is  a rare  but  treatable  cause  of hypertension  in ADPKD;
given  the  anatomical  complexities  these  patients  present,  careful  preoperative  planning  and  surgical
technique  are essential  to a favorable  outcome.
©  2015  The  Authors.  Published  by Elsevier  Ltd.  on behalf  of  Surgical  Associates  Ltd.  This  is  an  open
access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Autosomal dominant polycystic kidney disease (ADPKD) is the
most common inherited renal cystic disease, occurring in 1 of every
400–1000 live births. Arterial hypertension is present in 50–75%
of patients even before there is signiﬁcant loss of renal function.
The typical pathogenesis of hypertension in ADPKD involves cystic
compression of renal microvasculature, resulting in ischemia and
activation of the renin-angiotensin-aldosterone system [1,2]. It is
important to recognize that some patients may  have modiﬁable
secondary causes of hypertension, as well, given that cardiovascu-
lar disease is the main cause of death in this population, and early
detection and treatment of hypertension signiﬁcantly decrease the
risk for proteinuria, hematuria, decline in renal function, and mor-
bidity and mortality from valvular heart disease and aneurysms
[3–5].
Abbreviations: ACTH, adrenocorticotropic hormone; ADPKD, autosomal domi-
nant  polycystic kidney disease; PCC, pheochromocytoma; VHL, von Hippel Lindau.
∗ Corresponding author at: Department of Surgery, Hospital Clínic, University of
Barcelona, C/ Villarroel 170, 08036 Barcelona, Spain. Fax: +34 93 227 98 07.
E-mail address: ajhesshe@clinic.ub.es (A.J. Hessheimer).
2. Presentation of case
The patient is a 50-year-old man  with ADPKD with preserved
renal function, polycystic liver, and hypertension treated with four
agents, with blood pressure on presentation of 140/70 mmHg. He
has a family history of ADPKD (affected father); there is no family
history of neoplastic disease.
On routine imaging performed to monitor the progression of his
ADPKD, a right adrenal mass measuring 40 × 27 mm is detected.
Based on MRI  characteristics (intense and heterogeneous contrast
uptake and increased T2 signal intensity), the lesion is suggestive
of pheochromocytoma (PCC) versus adrenocortical carcinoma or
metastatic lesion of unknown primary (Fig. 1). The patient denies
any previous hypertensive crises, episodic headache, diaphoresis,
tachycardia, and/or palpitations, and metanephrines in plasma and
urine are within the reference ranges (Table 1). Given the size of
the lesion and the inability to exclude malignancy, the decision
is made to perform right adrenalectomy. A retroperitoneoscopic
approach is chosen in consideration of the size of the patient’s liver
(tip extending well below the umbilicus).
The patient is admitted preoperatively for blood pressure con-
trol and intravenous ﬂuid and salt loading. In the operating room,
after induction of general anesthesia and orotracheal intubation,
the patient is placed in prone position. A 1.5-cm incision is made
http://dx.doi.org/10.1016/j.ijscr.2015.07.015
2210-2612/© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. Contrast-enhanced cross-sectional imaging of the patient’s abdomen demonstrates a 40 × 27 mm lesion in the right adrenal gland (white arrows). The lesion has
heterogeneous contrast uptake and increased signal intensity on T2-weighted MRI  (A) and is suggestive of pheochromocytoma versus adrenocortical carcinoma or metastatic
lesion  of unknown primary. The lesion is situated posterior to the enlarged polycystic liver and inferior vena cava (B) and anterior and superior to the superior pole of the
polycystic right kidney (C, D).
Table 1
Laboratory values.
Value Reference range
Blood
Serum creatinine (mg/dL) 1.12 0.30–1.30
Serum sodium (mEq/dL) 142 135–145
Serum potassium (mEq/dL) 4.9 3.5–5.5
Serum cortisol (g/dL) 14.9 10–25
Serum ACTH (pg/mL) 41 10–60
Plasma aldosterone (ng/dL) 5.5 <30
Plasma renin activity (ng/mL*h) 0.88 0.5–2.3
Plasma free metanephrine (pg/mL) 18 <90
Plasma free normetanephrine (pg/mL) 118 <200
Urine
Fractionated epinephrine (mcg/24 h) 6.6 0.5–20
Fractionated norepinephrine (mcg/24 h) 50.6 15–80
Fractionated dopamine (mcg/24 h) 149 60–400
Fractionated metanephrine (mcg/24 h) 32 24–96
Normetanephrine (mcg/24 h) 184 75–375
Preoperative laboratory values. Plasma free metanephrines and urine fractionated
catecholamines and metanephrines are all within the reference ranges.
immediately caudal and parallel to the right twelfth rib, and blunt
dissection is used to enter the retroperitoneal space. The dissec-
tion is carried out laterally in order that a 5-mm trocar may  be
placed several centimeters to the right of the initial incision. A
12-mm Blunt Tip Trocar with an inﬂatable balloon (OMST12BT,
Covidien, Dublin, Ireland) is placed in the initial incision, the bal-
loon is inﬂated, and pneumoretroperitoneum is created, with a
maximum pressure of 25 mmHg.
Retroperitoneoscopy is performed using a 30◦ 10-mm endo-
scope. Further blunt dissection is performed medially in order to
place a third 10-mm trocar under direct visual control. The superior
pole of the right kidney, which is enlarged and presents multi-
ple cysts, is visualized and mobilized caudally. The right adrenal
gland with the lesion is visualized superiorly and adjacent to the
inferior vena cava. The gland is dissected circumferentially using
bipolar diathermy (LigaSureTM, Covidien), placed inside a laparo-
scopic specimen pouch (Endo CatchTM, Covidien), and extracted.
Intraoperatively, the patient presents a sudden decrease in
blood pressure when the right adrenal vein is ligated; in addi-
tion to intravenous ﬂuids, low-dose norepinephrine is required to
maintain mean arterial pressure >60 mmHg  for the ﬁrst several
post-operative hours. The patient is discharged from the intensive
care unit on the ﬁrst post-operative day. He no longer requires any
antihypertensive therapy.
Pathological examination of the surgical specimen reveals PCC
measuring 4.5 cm in its largest dimension.
3. Discussion
Pheochromocytoma is an uncommon tumor of neural crest
origin arising from adrenomedullary paraganglial tissue. The inci-
dence of PCC is between 2 and 8 cases per million persons per year
and peaks between the third and ﬁfth decades of life. It is the cause
of arterial hypertension in 0.1–0.4% of cases, and approximately
5% of patients with incidental adrenal masses have PCC. Among
patients with ADPKD, PCC is exceptionally rare: only two  other
cases have been reported in the medical literature [6,7], though
neither had concomitant polycystic liver.
Clinical signs and symptoms of PCC are the result of excess cate-
cholamine production. Between 90 and 100% of patients experience
arterial hypertension, which is episodic in half and continuous
in the remainder. Other symptoms include headache (70–90%),
diaphoresis (60–70%), and palpitations (50–70%). Clinical suspicion
for PCC may  be raised in patients with typical symptoms, resistant
hypertension, a family history of PCC or a familial genetic syndrome
that predisposes to PCC, or an incidentally discovered adrenal mass.
Given the present patient’s history of resistant hypertension, sus-
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picion might have been raised for PCC; the clinical scenario was
obscured, however, by his underlying diagnosis.
Up to one quarter of all PCC are hereditary and associated with
one of six pheochromocytoma syndromes: multiple endocrine neo-
plasia type 2; neuroﬁbromatosis type 1; von Hippel-Lindau (VHL);
and paraganglioma syndromes types 1, 3, and 4 [8,9]. In the present
patient with renal cystic disease and PCC, it is important to rule
out VHL. Von Hippel-Lindau disease occurs as the result of a muta-
tion in the VHL gene located on chromosome 3p25-26, which
encodes pVHL, a protein located in the cytoplasm and endoplas-
mic  reticulum and required for ciliogenesis. Apart from renal cysts,
manifestations of VHL include central nervous system heman-
gioblastoma, renal cell carcinoma, pancreatic cysts and islet cell
tumors, endolymphatic sac cysts and tumors, and cystadenomas of
the epididymis and broad ligament. Pheochromocytoma develops
in 15–20% of cases, with an average age at diagnosis of 16 years
[10]. Considering the present patient’s age, his family history of
ADPKD, and the absence of additional typical neoplastic lesions in
both himself and his family, a diagnosis of VHL can effectively be
ruled out.
The diagnosis of PCC is based on biochemical tests followed
by radiological imaging for tumor localization. Traditionally, bio-
chemical tests were performed to detect elevated levels of
catecholamines themselves; however, advances in the ability to
detect low levels of catecholamine metabolites together with a bet-
ter understanding of catecholamine metabolism have led to a shift
toward metabolite-based tests [11]. In adrenal medullary chromaf-
ﬁn cells, norepinephrine and epinephrine leak from storage vesicles
into the cytoplasm, where immediate monoamine degradation by
membrane-bound catechol-O-methyltransferase leads to the for-
mation of normetanephrine and metanephrine, respectively. This
process of catecholamine metabolism functions continuously and
independently from catecholamine release from the cell, making
tests to detect metanephrines particularly advantageous in tumors
that release catecholamines in low levels or in a discontinuous
fashion [12].
Currently, the most reliable test for the diagnosis of PCC is the
measurement of plasma free metanephrines; urine fractionated
metanephrines may  also be used, though somewhat less reliably
[13]. False positive results occur in the context of stress and cer-
tain drugs, while false negative results occur in relation to small
tumor size and intermittent catecholamine secretion, necessitat-
ing serial measurements to detect elevated values. In the present
patient with false negative tests, additional measurements would
have most certainly come back as elevated; they were not per-
formed, however, as the decision was made to resect his tumor
regardless.
Treatment of PCC is surgical and involves tumor removal after
alpha blockade. Surgical resection of PCC is a high-risk proce-
dure that should only be performed by experienced surgeons and
anesthesiologists. Intraoperative tumor manipulation may  result in
hypertensive crisis, which is managed with sodium nitroprusside,
phentolamine, or urapidil. Once tumor venous outﬂow has been
ligated, hypotension may  occur, which is best treated with intra-
venous ﬂuids, though a limited period of vasoactive therapy may
be required.
Adrenalectomy is performed for sporadic PCC, while adrenal-
sparing surgery is considered in hereditary cases. Minimally
invasive surgery (laparoscopy, retroperitoneoscopy) is the pre-
ferred approach. While laparoscopy may  be considered in patients
with polycystic kidneys only [14], achieving safe and adequate
access to the adrenal gland – the right gland, in particular – is very
difﬁcult when the liver is enlarged.
This is only the second case reported in the medical literature
of adrenalectomy performed in a patient with polycystic kidneys
and liver; one other group describes bilateral retroperitoneoscopic
adrenalectomy after ineffective transsphenoidal microadenomec-
tomy in a patient with an ACTH-secreting pituitary adenoma [15].
Given that PCC resection is a delicate operation and tumor manip-
ulation must be kept to a minimum, retroperitoneoscopy may  be
considered the approach of choice in a patient with polycystic kid-
neys and liver. The enlarged liver is anterior to the surgical ﬁeld and
does not pose an impediment to the operator, while the polycystic
kidney may  be retracted inferiorly or, alternatively, large cysts may
be unroofed and drained.
4. Conclusions
Pheochromocytoma is an exceptionally rare but treatable cause
of hypertension among ADPKD patients. Clinical suspicion for PCC
may  be raised in the presence of typical symptoms or refrac-
tory hypertension. Considering that PCC is much more commonly
associated with another renal cystic disease, VHL, this alternate
diagnosis must be ruled out. Treatment of PCC is surgical and should
only be undertaken by endocrine surgeons experienced in mini-
mally invasive surgery. When there is cystic affectation of the liver
in addition to the kidneys, a retroperitoneoscopic approach is the
approach of choice.
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